Paul Finley Detjen, M.D.

Paul Finley Detjen, M.D.

Paul Finley Detjen, M.D.

Profile

Personal Bio

Personal Interests

Mobile Care Foundation's involvement in the care of Chicago's school children having asthma.

Conditions & Procedures

Conditions

Allergic Drug Reactions, Allergies, Anaphylaxis, Asthma, Atopic Dermatitis, Bee Allergy, Eczema, Esophageal Disease, Food Allergies, Hives, Immunology, Immunotherapy, Pediatric Allergy, Pediatric Asthma, Pediatric Immunology, Sinusitis, Urticaria

Procedures

Allergy Shots, Rush Immunotherapy

General Information

Gender

Male

Affiliation

Independent Practitioner

Expertise

Pediatric Allergy & Asthma, Adult Allergy & Asthma

Academic Rank

Clinical Assistant Professor

Languages

English

Board Certified

Allergy & Immunology, Internal Medicine

Education, Training & Fellowships

Medical School

Washington University School of Medicine, 1984

Internship

Michael Reese/University of Chicago

Residency

Rush-Presbyterian-St Luke's Medical Center
Northwestern Feinberg School of Medicine

Fellowship

Northwestern Feinberg School of Medicine

Locations

A

Kenilworth Medical Associates

534 Green Bay Rd.
Kenilworth, IL 60043
847.256.5505
847.256.5567 fax

This location is not wheelchair accessible.

Insurance

Every effort has been made to ensure the accuracy of the information in this directory. However, some changes may occur between updates. Please check with your provider to ensure that he or she participates in your health plan.

BCBS HMOI
BCBS: Blue Advantage
NorthShore Employee Network II (EPO Plus & CDHP)

Publications

  • Success of a comprehensive school-based asthma intervention on clinical markers and resource utilization for inner-city children with asthma in Chicago: the Mobile C.A.R.E. Foundation's asthma management program.

    The Journal of asthma : official journal of the Association for the Care of Asthma 2007 Mar

    Authors: Patel B,
    Abstract
    Children with asthma in low-income households in Chicago were participants in a school-based mobile van clinic, Mobile C.A.R.E. Our objective was to investigate whether long-term follow-up changed clinical markers and resource utilization. Children were evaluated by a pediatrician in a mobile allergy clinic and classified and treated based on National Asthma Education and Prevention Program (NAEPP) guidelines. Intervention consisted of assessment of allergic environment with avoidance recommendations, institution of appropriate controller therapy and inhaler technique, education on asthma and asthma management, and expectations for asthma control. Over 20,000 children were screened, 2041 were examined at least once, and 677 children had four follow-up visits. With follow-up, there was a decrease in hospitalizations and emergency room visits. Symptomatic markers (daytime and nighttime cough, wheezing, and dyspnea symptoms), frequency of rescue inhaler use, and a quality-of-life score improved from baseline. These findings suggest that ongoing school interventions may reduce resource utilization and improve clinical symptoms. Primary care physicians may be able to deliver specialized care to large numbers of inner-city children with asthma.
    PMID: 17454325 [PubMed - as supplied by publisher]
  • Hymenoptera allergy.

    Cutis 2005 Jul

    Authors: Ganz M,
    Abstract
    This 3-week prospective, randomized, double-masked, parallel-group study compared ketotifen fumarate 0.025% ophthalmic solution and olopatadine hydrochloride 0.1% ophthalmic solution in 66 patients with seasonal allergic conjunctivitis. The drugs were instilled twice daily. Signs and symptoms were assessed on days 5 (visit 2) and 21 (visit 3). Other efficacy variables were the responder rate (patients with excellent or good global efficacy on days 5 and 21) and patient and investigator ratings of global efficacy. Comfort was evaluated immediately after instillation of the first drop and at each follow-up visit. The frequency of adverse events was the safety assessment. The responder rate was higher with ketotifen than with olopatadine on day 5 (72% vs 54% for patient assessment, 88% vs 55% for investigator assessment) and day 21 (91% vs 55%, 94% vs 42%). Global efficacy ratings were higher with ketotifen, and severity scores for hyperemia and itching were significantly lower. Both drugs elicited comparable comfort ratings. The most common adverse events were burning/stinging and headache.
    PMID: 16144293 [PubMed - as supplied by publisher]
  • Atrial fibrillation associated with anaphylaxis during venom and pollen immunotherapy.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2002 Aug

    Authors: Patel SC,
    Abstract
    Electrographic changes after insect stings have been reported both with and without systemic symptoms. To our knowledge, however, there have been no reported cases of arrhythmias in the maintenance phase of venom or pollen immunotherapy.
    We report a case of a patient who developed paroxysmal atrial fibrillation after receiving venom and pollen immunotherapy. This patient was initially evaluated in an outpatient setting, and the events described occurred at an allergist's private office. We believe this is an atypical presentation and would be very pertinent to the practicing allergist.
    This patient was under the care of a clinical allergist in a private practice with associations to a teaching hospital. Interventions were as described in the body of the paper, more specifically venom and pollen maintenance immunotherapy followed by two doses of 0.3 mL of 1:1,000 concentration epinephrine intramuscularly.
    Patient was found to be in atrial fibrillation along with systemic symptoms immediately after administration of immunotherapy. After epinephrine administration, patient converted back to normal sinus rhythm and systemic symptoms resolved.
    Atrial fibrillation is an atypical presentation of a systemic reaction to immunotherapy.
    PMID: 12197580 [PubMed - as supplied by publisher]
  • Communication and planning play a vital role in care.

    Oncology nursing forum

    Authors: Patterson R,
    Abstract
    Evaluation of therapy for Stevens-Johnson syndrome was initiated as a retrospective analysis and then extended to a prospective series of patients treated with corticosteroids. This report extends the initial prospective study of patients with Stevens-Johnson syndrome treated with corticosteroids and evaluates the total series of 41 patients relative to outcome and the presumptive etiology. We propose that management of Stevens-Johnson syndrome requires corticosteroid therapy and that the survival of patients with Stevens-Johnson syndrome may depend on this therapy. No fatalities or adverse effects due to corticosteroids were noted. Stevens-Johnson syndrome due to a drug, a drug metabolite or viral infection may mimic a graft-versus-host reaction in which the patient rejects skin, mucous membrane, kidney or liver cells to which the drug, drug metabolite, or virus has bound. Corticosteroids suppress the inflammatory rejection until the activating agent has been eliminated.
    PMID: 10573677 [PubMed - as supplied by publisher]
  • Stinging insect allergy and venom immunotherapy.

    Allergy proceedings : the official journal of regional and state allergy societies

    Authors: Detjen PF,
    Abstract
    We describe a 36-year-old man with recurrent Stevens-Johnson syndrome, which became progressively more severe over a 13-year period. His episodes were apparently preceded by herpes simplex virus oral mucosal infections. A management protocol, including immediate therapy with acyclovir and prednisone at the onset of herpes simplex virus oropharyngitis, is outlined. This management strategy has successfully prevented four subsequent episodes of progression to Stevens-Johnson syndrome. Thus, Stevens-Johnson syndrome associated with herpes simplex virus may be prevented by early use of acyclovir and prednisone.
    PMID: 8514163 [PubMed - as supplied by publisher]
  • Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS.

    Allergy proceedings : the official journal of regional and state allergy societies

    Authors: Patterson R,
    Abstract
    To confirm that corticosteroids are beneficial in the treatment of Stevens-Johnson syndrome (SJS), 15 patients with the syndrome were evaluated by the same group of physicians over 2 years. All patients had cutaneous and most had mucosal lesions. Patients were treated with corticosteroids ranging from prednisone 40 mg daily to methylprednisolone 750 mg daily. The same group of physicians participated in the management of these patients until recovery. No deaths occurred among the 15 patients. Recovery was complete in all cases, and there was no residual skin, mucosal, or visceral damage except for minimal scarring in one patient. In some cases, reversal of disease after onset of corticosteroid therapy was sufficiently dramatic to demonstrate a benefit. The use of corticosteroids in the treatment of SJS remains controversial. We conclude that corticosteroids are beneficial in treatment of the syndrome. They may be lifesaving in some patients and should be the standard of therapy. SJS should be considered to be erythema multiforme with either bullous lesions or visceral involvement or both.
    PMID: 1587471 [PubMed - as supplied by publisher]
× Alternate Text